Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Microbot Medical ( (MBOT) ).
On March 10, 2026, Microbot Medical announced it would participate for the first time in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16–19, 2026. CEO Harel Gadot was scheduled to present live on March 19, 2026, highlighting recent achievements from LIBERTY’s limited market release and outlining key market growth drivers tied to its commercialization strategy.
The company framed the Oppenheimer appearance as evidence of rising institutional and market interest in the LIBERTY system, which began a limited market release in late 2025 and is slated for a full launch at the Society of Interventional Radiology conference in April 2026. Management also arranged one-on-one meetings with institutional investors, underscoring efforts to deepen adoption of its robotic platform and support long-term value creation for stakeholders.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the first FDA-cleared, single-use, remotely operated robotic solution designed to enhance precision, efficiency and safety in peripheral vascular interventions, targeting hospitals and interventional specialists seeking to modernize care.
Average Trading Volume: 1,937,608
Technical Sentiment Signal: Hold
Current Market Cap: $164.5M
See more insights into MBOT stock on TipRanks’ Stock Analysis page.